Patients will be randomized to 1 of 2 arms:
ARM 1: Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive placebo orally once daily on days 1-30. Treatment repeats every 30 days for up to 6 courses over 6 months in the absence of disease progression or unacceptable toxicity.
ARM 2: Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive oral apalutamide on Days 1-30. Treatment repeats every 30 days for up to 6 courses over 6 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for 3 years, and then yearly thereafter.
This study is for patients who have been diagnosed with high-risk neuroblastoma. The purpose of this study is to learn if the treatment you received for your high-risk neuroblastoma has affected your health overtime. Participants can expect to be in this study for up to 12 weeks.
This study is for patients who have mantle cell lymphoma. The investigational drugs used in this study are rituxan hycela and rituximab. The purpose of this research study is to determine whether an autotransplant improves survival in MCL patients who have achieved an excellent (MRD-negative) first complete remission (CR). Participants can expect to be in this study for up to 3 years and then followed for up to 10 years to monitor their health.
The purpose of this study is to find out whether patients with pancreatic cancer will live longer when receiving treatment with nab-Paclitaxel and Gemcitabine, a standard chemotherapy regimen, given in combination with a new drug, BBI-608, or live longer when receiving treatment with nab-Paclitaxel and Gemcitabine alone for pancreatic cancer. The length of participation for this study will continue until your doctor feels you are no longer benefitting from your treatment. This study is expected to take 2-3 years to complete. This research is being done to improve on existing treatments for pancreatic cancer.
The objective of this study is to determine potential factors that contribute to late-stage diagnosis and treatment of HPV-positive and HPV-negative oropharyngeal tumors. We have developed a voluntary survey that will be given to patients treated at the MUSC Head and Neck Tumor Center. The survey consists of subsections that identify general HPV knowledge, timeline to diagnosis and treatment, educational background, and sociodemographic characteristics. The participating patients will be given the Short Test of Functional Health Literacy (S-TOFHLA) with the survey. The survey and health literacy data will be used to assess correlations between these factors and the patients stage of cancer at diagnosis. This study will also compare a chart review of prospective patients with retrospective chart review of former oropharyngeal cancer patients. The chart review will include data such as: stage of cancer at diagnosis, treatment, sequence of intervention for diagnosis and treatment, type of biopsy, and types of doctors involved in diagnosis and treatment.
Physicians currently have difficulty getting a biopsy of lung spots that are far out from the center of the lung. The bronchoscopes that are used to reach these spots currently are sometimes difficult to maneuver and are unable to reach far to these spots because of the large size of the bronchoscope. This study will test a new robotic scope that uses navigation software to find the distant spots in the lung so physicians can get a biopsy.
The purpose of this study is to see whether an investigational drug called CDX-3379 combined with cetuximab, a monoclonal antibody that targets a protein called EGFR, will shrink tumors for subjects with head and neck squamous cell carcinoma (HNSCC). This study is for patients who have been diagnosed with HNSCC and who have previously received cetuximab but who have since experienced progression. Both the investigational drug, CDX-3379, and cetuximab are administered intravenously (into a vein). Subjects can expect to participate in the study for 2 years or longer.
This study is for patients that have been diagnosed with advanced small cell lung cancer. The investigational drug in this study is Nivolumab (OPDIVO). The purpose of this study is to compare any good and bad effects of using nivolumab along with the usual chemotherapy regimen of cisplatin/carboplatin and etopiside to using the usual chemotherapy approach alone. Participants can expect to be in this study receiving drug and chemotherapy for up to a month with follow up for up to 5 years.
This observational, cross-sectional study will recruit 200 YA survivors. Data will be collected using a web-based interface and will capture physical, psychosocial and cognitive late effects; work ability; work-related outcomes, including labor force participation, occupation, work place characteristics, and educational attainment; survivor characteristics; and cancer diagnosis/treatment information (from clinical records). Inclusion criteria includes: (1) current age 25-34 years; (2) ?2 to <10 years post-cancer diagnosis; (3) not in active cancer treatment (allowing for maintenance or hormonal therapies); and (4) diagnosed with first cancer (any type except types listed in exclusion criteria in section 4.2) at age ?15 years. Must be able to read and understand English to understand and willingly sign informed consent.
This study is for subjects that have been diagnosed with multiple myeloma. The investigational drug in this study is atezolizumab.The purpose of this study is to test the safety of various combinations of an experimental (not yet approved by the U.S. Food and Drug Administration [FDA] or any other regulatory authority outside the United States) drug called atezolizumab given with daratumumab, lenalidomide, and/or pomalidomide with or without dexamethasone (all approved by the FDA for the treatment of multiple myeloma) at different dose levels and to find out what effects, good or bad, the combination of these drugs has on you. Participants can expect to be in this study for 36 months.